Organization | Viroclinics Biosciences B.V.

Viroclinics Biosciences B.V. Report issue

For profit Phase 1

Founded: Rotterdam Netherlands

Organization Overview

First Clinical Trial

2021

NCT04529538

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Viroclinics Biosciences B.V.

Active Ingredients

Drugs in Phase 1 Trials (4)

live oral poliovirus type 1, 2 and 3 (Trivalent oral polio vaccine - Sabin) (1 trial)

monovalent oral polio vaccines (mopv1) (MOPV1) (1 trial)

novel oral polio vaccine type 1 (nopv1) (1 trial)

novel oral polio vaccine type 3 (nopv3) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Poliomyelitis (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 1
# of Trial APIs: 4